releasing of aromatase of lung cancer tissue, which catalyzes androgen to change into estrogen, into external blood might be the major reason of the increase of estradiol and the decrease of testosterone in external blood.

frequent coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer might suggest some functional correlation between aromatase and estrogen receptor beta

CYP19A1 polymorphisms are involved in the risk for lung atypical adenomatous hyperplasia (AAH)and bronchioloalveolar carcinoma (BAC) in the lungs by causing differences in estrogen levels.

Data show that the L858R mutation of EGFR is associated with SNP of estrogen biosynthesis and metabolism genes CYP17, CYP19A1, ERalpha, and COMT in never-smoking female lung adenocarcinoma patients.

abberant gene expression in non-small cell lung cancer

this brief review is focused on possible roles of lung carcinoma intratumoral aromatase.[review]

higher levels of expression in conjunction with higher estrogen receptor beta levels predict worse survival in non-small cell lung cancer

No association was found between CYP19A1 polymorphisms and lung cancer in Singapore Chinese women.

Polymorphisms of CYP19A1 may be related with the increased risk for lung cancer.

Aromatase is a candidate prognostic factor in patients with lung adenocarcinoma, especially in those with EGFR mutations, and may also be a beneficial therapeutic target in those patients.